Details of the Drug Combination

General Information of Drug Combination (ID: DC0IG6W)

Drug Combination Name
BIO-300 Altretamine
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Altretamine   DMKLAYG
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: BT-549
Zero Interaction Potency (ZIP) Score: 5.84
Bliss Independence Score: 8.81
Loewe Additivity Score: 6.15
LHighest Single Agent (HSA) Score: 8.66

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Altretamine
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [4]
Altretamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Carcinoma DC9EGLF MCF7 Investigative [1]
High grade ovarian serous adenocarcinoma DCZLHXP OVCAR-5 Investigative [6]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
5 Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.